Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hereditary antithrombin III deficiency: biochemical aspects.

G Sas

    Haematologia
    |January 1, 1984
    PubMed
    Summary

    Congenital antithrombin-III (AT-III) deficiency, a thrombophilia risk, presents diverse forms. Research categorizes these into quantitative (Type 1) and qualitative (Type 2) deficiencies, with Type 2 showing functional AT-III molecule defects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden.

    The hematology journal : the official journal of the European Haematology Association·2002
    Same author

    [Screening for violence against women. Validation and feasibility studies of a French screening tool].

    Canadian family physician Medecin de famille canadien·2001
    Same author

    Identification of mutations in 15 Hungarian families with hereditary protein C deficiency.

    British journal of haematology·2000
    Same author

    Application of the Woman Abuse Screening Tool (WAST) and WAST-short in the family practice setting.

    The Journal of family practice·2000
    Same author

    [Clinical evaluation of factors VIII and IX manufactured in Hungary, based on results of the first half year].

    Orvosi hetilap·1998
    Same author

    [Indirect methods in the genetic diagnosis of hemophilia A].

    Orvosi hetilap·1998

    Area of Science:

    • Biochemistry
    • Hematology
    • Genetics

    Background:

    • Congenital antithrombin-III (AT-III) deficiency is a known risk factor for thrombophilia.
    • Early classifications identified homogeneous quantitative deficiencies (Type 1) affecting AT-III's functional and antigenic properties.
    • Subtypes 1a and 1b were distinguished based on heparin affinity.

    Purpose of the Study:

    • To detail the evolution of understanding congenital AT-III deficiency.
    • To highlight the discovery and characteristics of qualitative AT-III disorders (Type 2).
    • To present recent observations of novel Type 2 AT-III variants.

    Main Methods:

    • Review of historical family descriptions and clinical data.
    • Biochemical and functional assays of AT-III molecules.
    • Genetic analysis of affected individuals.

    Main Results:

    • Initial AT-III deficiency (Type 1) involved decreased antigen and function.
    • Type 1 was sub-classified into 1a and 1b based on heparin binding.
    • Type 2 deficiency, first identified in 1974 (AT-III Budapest), shows normal antigen levels but absent or reduced function.
    • Recent variants of Type 2 exhibit loss of specific AT-III functions.

    Conclusions:

    • Congenital AT-III deficiency is heterogeneous, encompassing quantitative and qualitative defects.
    • Type 2 disorders represent a distinct category with functional AT-III molecule abnormalities.
    • Ongoing research continues to identify new variants of qualitative AT-III deficiency, expanding our knowledge of thrombophilia.

    Related Experiment Videos